

SYNAGIS (palivizumab)

Pre - PA Allowance

None

Prior-Approval Requirements

Diagnosis

Prevention of infection caused by Respiratory Syncytial virus (RSV)

AND ONE of the following:

1. Less than 12 months old at the start of RSV season*

AND ONE of the following:

- a. Hemodynamically significant congenital heart disease (e.g. congestive heart failure, or pulmonary hypertension)
- b. Congenital airway abnormality that impairs the ability to clear secretions
- c. Neuromuscular disorder that decreases the ability to manage airway secretions
- d. Chronic lung disease (CLD) in infants less than 32 weeks gestational age
- e. Preterm infants less than 29 weeks gestational age
- 2. Child in second year of life (between 12 months and less than 24 months of age) at the start of RSV season*

AND ONE of the following:

- 1. Cardiac transplant or bypass patients
- 2. Severely immunocompromised
- 3. Chronic lung disease (CLD) in infants less than 32 weeks gestational age requiring continued medical support

*RSV season generally lasts from November through April in most locations in the United States. Consult the CDC National Respiratory and Enteric Virus Surveillance System (NREVSS) for RSV surveillance at https://www.cdc.gov/surveillance/nrevss/rsv/state.html.

Prior - Approval Limits

Duration6 months (PA may start 1 month prior to the RSV season*)Each new RSV season is the initiation of therapy